- Crucell
-
Crucell N.V. Type Privately held naamloze vennootschap; subsidiary Industry Biotechnology Founded 2000 Headquarters Leiden, Netherlands Key people Ronald Brus (CEO), Jan Pieter Oosterveld (Chairman of the supervisory board) Products Vaccines and antibodies Revenue €329.8 million (2010)[1] Operating income (€34.3 million) (2010)[1] Profit (€27.6 million) (2010)[1] Total assets €967.1 million (end 2010)[1] Total equity €786.4 million (end 2010)[1] Owner(s) Johnson & Johnson Employees 1,250 (2009)[2] Website www.crucell.com Crucell is a biotechnology company specializing in vaccines and antibodies. The firm, a subsidiary of Johnson & Johnson, is headquartered in Leiden, Netherlands. Crucell shares were previously listed on the Euronext Amsterdam exchange and formed part of the AMX index until April 2011, when J&J completed a tender offer for the company.
Contents
History
In 1993 Introgene, Crucell’s predecessor, was established as a spin-off of Leiden University. The company formed a partnership with Genzyme to collaborate on its vector technology and viral-based products. In 1999 the company founded Galapagos Genomics as a joint venture together with Tibotec. In 2000 IntroGene acquired U-Bisys to form Crucell.
In 2006, Crucell and Swiss Berna Biotech; Swedish SBL Vaccines and US-based Berna Products joined forces to become the sixth largest vaccine company worldwide, with their own clinical programs.
On 7 January 2009 Crucell released a press release saying Crucell and Wyeth were in discussion on a merger of the two companies. On 26 January 2009 Crucell released another press release saying the discussions on a combination of Crucell and Wyeth was discontinued due to Pfizer's acquisition of Wyeth.
On 28 September 2009 Johnson & Johnson bought 18% stake in Crucell for €302 million in order to collaborate on the development of a flu vaccine.[3] This follows in the wake of Crucell's discovery of CR6261, a potent human antibody that neutralizes a broad range of influenza A viruses. J&J agreed to acquire the rest of the company in October 2010, taking its stake to over 95% by February 2011[4] and delisting the company from stock exchanges two months later.[5]
Vaccine products
Paediatric
- Quinvaxem
- Hepavax-Gene
- MoRu-Viraten
- Epaxal-Junior
Travel and endemic
- Epaxal
- Vivotif
- Dukoral
Respiratory
- Inflexal V
References
- ^ a b c d e "Annual Results 2010". Crucell. http://hugin.info/132631/R/1485773/420938.pdf. Retrieved 27 February 2011.
- ^ "Annual Report 2009". Crucell. http://crucell.com/annual_report_2009/pdfs/Crucell_AR09_Complete.pdf. Retrieved 2010-05-23.
- ^ Gray-Block, Aaron (28 September 2009). "Johnson & Johnson buys 18 pct stake in Crucell". Reuters. http://www.reuters.com/article/rbssPharmaceuticals%20-%20Generic%20&%20Specialty/idUSLS21205620090928. Retrieved 28 September 2009.
- ^ Solsman, Joan E. (17 February 2011). "J&J: Sufficient Number Of Crucell Holders Tender Shares". The Wall Street Journal. Dow Jones Newswires. http://online.wsj.com/article/BT-CO-20110217-717650.html. Retrieved 27 February 2011.
- ^ Gray-Block, Aaron (11 April 2011). "Crucell to be delisted after J&J buyout". Reuters. http://www.reuters.com/article/2011/04/11/crucell-idUSLDE73A0FR20110411. Retrieved 16 April 2011.
External links
Johnson & Johnson William C. Weldon, Chairman & CEO
Past CEOs and presidents: Robert Wood Johnson I • James Wood Johnson • Robert Wood Johnson II • Robert Wood Johnson III • Philip B. Hofmann • Richard B. Sellars • James E. Burke • Ralph S. Larsen
Selected subsidiariesALZA Corporation • Centocor • Cilag • Crucell • DePuy, Inc. • Ethicon Endo-Surgery, Inc. • Ethicon, Inc. • Independence Technology, LLC • J&J PRD •Janssen Pharmaceutica • LifeScan • McNeil Consumer & Specialty Pharmaceuticals • McNeil Nutritionals • Ortho-McNeil Pharmaceutical • Ortho-Neutrogena • Penaten • Tibotec
Major brandsAnnual revenue: $63.75 billion USD 4.3% Annual net income: $12.95 billion USD 22.4% (FY 2008) · Employees: 118,700 ·
Stock symbol: NYSE: JNJ · Website: jnj.comThis article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.